New study highlights burden on shingles patients

Sanofi Pasteur MSD is supporting the Department of Health’s national shingles immunisation programme in its second year, offering vaccination to people aged 70, 78 and 79 years from 1 September.  This next cohort of eligible patients will present at GP surgeries as new research highlights the burden of post-herpetic neuralgia (PHN) on patients’ quality of life, and calls for vaccination against shingles and PHN to reduce the impact on individual patients, healthcare systems and society as a whole. Patients in the Zoster Quality of Life Study (ZQOL) with a confirmed diagnosis of PHN, reported experiencing pain in the area of